U.S. markets open in 8 hours 24 minutes
  • S&P Futures

    4,119.75
    -6.75 (-0.16%)
     
  • Dow Futures

    33,666.00
    -37.00 (-0.11%)
     
  • Nasdaq Futures

    13,743.00
    -51.25 (-0.37%)
     
  • Russell 2000 Futures

    2,181.50
    -2.50 (-0.11%)
     
  • Crude Oil

    62.61
    +0.17 (+0.27%)
     
  • Gold

    1,781.80
    +3.40 (+0.19%)
     
  • Silver

    25.90
    +0.06 (+0.23%)
     
  • EUR/USD

    1.2032
    -0.0009 (-0.07%)
     
  • 10-Yr Bond

    1.5620
    0.0000 (0.00%)
     
  • Vix

    18.68
    +1.39 (+8.04%)
     
  • GBP/USD

    1.3922
    -0.0015 (-0.11%)
     
  • USD/JPY

    108.0300
    -0.0400 (-0.04%)
     
  • BTC-USD

    55,243.20
    +483.46 (+0.88%)
     
  • CMC Crypto 200

    1,267.59
    +33.18 (+2.69%)
     
  • FTSE 100

    6,859.87
    -140.21 (-2.00%)
     
  • Nikkei 225

    28,525.84
    -574.54 (-1.97%)
     

Recro Pharma: Q2 Earnings Insights

  • Oops!
    Something went wrong.
    Please try again later.
Benzinga Insights
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

Shares of Recro Pharma (NASDAQ:REPH) were flat in pre-market trading after the company reported Q2 results.

Quarterly Results

Earnings per share decreased 92.31% over the past year to ($0.25), which missed the estimate of ($0.16).

Revenue of $15,522,000 decreased by 50.34% year over year, which missed the estimate of $18,880,000.

Guidance

Earnings guidance hasn't been issued by the company for now.

Revenue guidance hasn't been issued by the company for now.

Conference Call Details

Date: Aug 10, 2020

View more earnings on REPH

Time: 08:00 AM

ET Webcast URL: https://edge.media-server.com/mmc/p/3xhm9v2z

Price Action

52-week high: $19.21

52-week low: $3.99

Price action over last quarter: down 9.22%

Company Profile

Recro Pharma Inc is a contract development and manufacturing company. The company is engaged in the development, formulation, regulatory support, manufacturing, and packaging of oral solid dose drug products. Its product portfolio includes Ritalin LA; Focalin XR; Verelan PM, SR and Verapamil PM; Verapamil SR and Zohydro ER.

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.